[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 6 of about 6
1. Piepoli A, Cotugno R, Merla G, Gentile A, Augello B, Quitadamo M, Merla A, Panza A, Carella M, Maglietta R, D'Addabbo A, Ancona N, Fusilli S, Perri F, Andriulli A: Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med Genomics; 2009;2:11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour.
  • BACKGROUND: Aberrant DNA methylation of CpG islands of cancer-related genes is among the earliest and most frequent alterations in cancerogenesis and might be of value for either diagnosing cancer or evaluating recurrent disease.
  • METHODS: The validation assay was performed in a different set of 8 patients with colorectal cancer (CRC) by means quantitative reverse-transcriptase polymerase chain reaction analysis.
  • NDRG2 hypermethylation was also detected in 8 out of 30 (27%) primary CRC tissues and was significantly associated with advanced AJCC stage IV.
  • Normal colon tissues were not methylated.
  • CONCLUSION: The findings highlight the usefulness of combining gene expression patterns and epigenetic data to identify tumour biomarkers, and suggest that NDRG2 silencing might bear influence on tumour invasiveness, being associated with a more advanced stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9116-21 [19010880.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Reprod Toxicol. 2007 Apr-May;23(3):297-307 [17046196.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39159-68 [17050536.001]
  • [Cites] BMC Bioinformatics. 2006;7:387 [16919171.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1121-5 [16699174.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):152-6 [16645200.001]
  • [Cites] Hypertension. 2005 Dec;46(6):1227-35 [16286565.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6773-9 [16061659.001]
  • [Cites] BMC Genomics. 2005;6:59 [15854232.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1904-9 [15790842.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1244-50 [15735008.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3518-21 [15526377.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6690-8 [10490608.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Biochem Biophys Res Commun. 1983 Feb 28;111(1):47-54 [6187346.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18623-32 [14985363.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):95-101 [14534800.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] FEBS Lett. 2003 Oct 23;553(3):413-8 [14572661.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):342-7 [12845671.001]
  • [Cites] Lancet Oncol. 2003 Jun;4(6):351-8 [12788407.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6820-2 [12460892.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6645-50 [12438262.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Mol Cell Biochem. 2002 Jan;229(1-2):35-44 [11936845.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Genomics. 2001 Apr 1;73(1):86-97 [11352569.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 13;270(2):581-7 [10753667.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):854-65 [10982779.001]
  • [Cites] BMC Cancer. 2007;7:192 [17935612.001]
  • (PMID = 19257893.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2660908
  •  go-up   go-down


2. Jung SH, Kim HC, Yu CS, Chang HM, Ryu MH, Lee JL, Kim JS, Kim JC: [Clinicopathologic characteristics of colorectal neuroendocrine tumor]. Korean J Gastroenterol; 2006 Aug;48(2):97-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics of colorectal neuroendocrine tumor].
  • BACKGROUND/AIMS: Colorectal neuroendocrine carcinoma is a rare neoplasm exhibiting fulminant progression and having poor prognosis.
  • RESULTS: Ten patients (0.2%) with colorectal neuroendocrine tumors were identified from 4,512 patients with colorectal cancer; ten neuroendocrine carcinomas and three adenocarcinomas with neuroendocrine differentiation.
  • Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse colon and cecum, respectively.
  • All patients were advanced at the time of diagnosis, with AJCC TNM staging: stage IIIB (n=2), stage IIIC (n=3), and stage IV (n=8).
  • Five patients who received chemotherapy showed median survival of 32 months (stage III) and 17.5 months (stage IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biopsy. Chromogranin A / analysis. Chromogranin A / immunology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Synaptophysin / analysis. Synaptophysin / immunology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929153.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
  •  go-up   go-down


3. Mehta PP, Griffin J, Ganta S, Rangraj M, Steichen F: Laparoscopic-assisted colon resections: long-term results and survival. JSLS; 2005 Apr-Jun;9(2):184-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic-assisted colon resections: long-term results and survival.
  • Anecdotal reports in the literature describe port-site and incisional tumor implantation in patients undergoing laparoscopic-assisted colectomies for colorectal malignancies.
  • This raises concerns about whether these incisional tumor sites are more common in these patients and whether their survival is compromised by the laparoscopic technique.
  • METHODS: The authors reviewed data from 110 patients who underwent laparoscopic-assisted colectomies for colorectal cancer to determine the long-term results and survival and to compare the safety and efficacy of laparoscopic-assisted colectomy to the safety and efficacy of open colectomy.
  • The American Joint Committee on Cancer staging for colorectal carcinomas and the Kaplan-Meier method were used to determine the survival curves.
  • RESULTS: Laparoscopic-assisted colon resections for colorectal malignancies were performed in 110 patients.
  • The ten-year survival rates for the various stages were 78% for stage I, 33% for stage II, 30% for stage III, and 0% for stage IV.
  • CONCLUSION: Laparoscopic-assisted colon resection of colorectal carcinomas is technically feasible and safe.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2000 Sep;66(9):841-3 [10993612.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1296-306 [11578282.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):590-606 [11685021.001]
  • [Cites] Dis Colon Rectum. 1983 Sep;26(9):571-2 [6223795.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):225-36 [7670682.001]
  • [Cites] Am Surg. 2000 Mar;66(3):245-8; discussion 248-9 [10759193.001]
  • [Cites] Dis Colon Rectum. 1996 Feb;39(2):200-7 [8620788.001]
  • [Cites] Ann Surg. 1996 Jun;223(6):790-6; discussion 796-8 [8645052.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):326-34 [9527054.001]
  • [Cites] Ann Surg. 1999 Apr;229(4):487-92 [10203080.001]
  • [Cites] Dis Colon Rectum. 1999 Mar;42(3):327-32; discussion 332-3 [10223751.001]
  • [Cites] Surg Laparosc Endosc. 1995 Dec;5(6):468-71 [8611995.001]
  • (PMID = 15984707.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3015573
  •  go-up   go-down


5. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • There was not a significant difference in survival by hospital type or year of diagnosis.
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404066.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Kim JS, Hur H, Min BS, Sohn SK, Cho CH, Kim NK: Oncologic outcomes of self-expanding metallic stent insertion as a bridge to surgery in the management of left-sided colon cancer obstruction: comparison with nonobstructing elective surgery. World J Surg; 2009 Jun;33(6):1281-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic outcomes of self-expanding metallic stent insertion as a bridge to surgery in the management of left-sided colon cancer obstruction: comparison with nonobstructing elective surgery.
  • BACKGROUND: Self-expanding metallic stents (SEMS) have been used as a bridge to surgery in patients with obstruction by colorectal cancer, but the oncologic safety of this technique has not yet been established.
  • METHODS: Between October 1999 and July 2007, 35 patients who had left-sided colon malignancy obstruction and underwent surgical resection after SEMS insertion (group A) were matched to 350 patients who underwent elective surgery for nonobstructing left-sided colon cancer based on stage II, III, and IV malignancies according to the 2001 American Joint Committee on Cancer (group B).
  • CONCLUSIONS: These data show that insertion of SEMS as a bridge to surgery in the management of left-sided colon cancer obstruction is possibly associated with adverse oncologic outcomes compared with nonobstructing elective surgery, but it is unclear what magnitude of this effect is related to the underlying obstruction rather than to the SEMS.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Int Surg. 1992 Oct-Dec;77(4):251-5 [1335999.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):444-50 [14994110.001]
  • [Cites] IARC Sci Publ. 1993;(121):1-806 [8258476.001]
  • [Cites] Br J Surg. 1994 Sep;81(9):1270-6 [7953385.001]
  • [Cites] Dis Colon Rectum. 2002 Mar;45(3):401-6 [12068202.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):24-30 [17592286.001]
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):792-7 [6389051.001]
  • [Cites] Ann Surg Oncol. 2002 Jul;9(6):574-9 [12095974.001]
  • [Cites] Dis Colon Rectum. 2000 Nov;43(11):1522-7 [11089586.001]
  • [Cites] Gastrointest Endosc. 2001 Apr;53(4):524-7 [11275904.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):266-9 [15019920.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):483-8 [16555262.001]
  • [Cites] Radiology. 1998 Feb;206(2):415-21 [9457194.001]
  • [Cites] Gastrointest Endosc. 2007 Nov;66(5):931-6 [17767930.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10 Suppl):S44-9 [14530657.001]
  • [Cites] Br J Surg. 2007 Sep;94(9):1151-4 [17541987.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1455-61 [15486741.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2005 Oct;15(4):757-71 [16278137.001]
  • [Cites] Br J Surg. 1992 Aug;79(8):839-41 [1393489.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):2051-7 [15447772.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1429-33 [14598426.001]
  • (PMID = 19363580.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement